PCRX Stock Analysis: Buy, Sell, or Hold?
PCRX - Pacira BioSciences, Inc. Common Stock
$23.53
0.49 (2.13%)
▲
5d:
-0.47%
30d:
+0.43%
90d:
+9.7%
BUY
HIGH Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Get Alerted When PCRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PCRX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: PCRX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$47.02
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$29.19
19.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PCRX is currently trading at $23.53, which is considered slightly low relative to its 30-day fair value range of $23.14 to $24.99. The stock's valuation (Forward PE: 6.5) is in line with its historical norms (6.7). Remarkably, the market is currently pricing in an annual earnings decline of 0.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PCRX is showing sideways momentum. Immediate support is located at $22.30, while resistance sits at $27.13.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $29.29 (+24.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PCRX is showing sideways momentum. Immediate support is located at $22.30, while resistance sits at $27.13.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $29.29 (+24.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$23.14 -
$24.99
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 24.5% below Wall St target ($29.29)
Trading Range Analysis
30-Day Trading Range
$23.14 -
$24.99
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$22.31
Resistance Level
$27.13
Current Trend
Sideways
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.53
Wall Street Target
$29.29
(+24.5%)
Revenue Growth (YoY)
5.0%
Earnings Growth (YoY)
-30.0%
Profit Margin
0.7%
Valuation Discount vs History
-0.9% cheaper
PE vs Historical
6.5 vs 6.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.9%
(market-implied from PE analysis)
1-Year Target
$23.32
(-1%)
2-Year Target
$23.11
(-2%)
3-Year Target
$22.90
(-3%)
3-Yr Target (if PE normalizes)
(PE: 7→7)
$23.50
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 25.2%)
$155.98
(+563%)
Base:
(SPY PE: 6.5, Growth: 25.2%)
$46.21
(+96%)
Bear:
(PE: 5.6, Growth: 25.2%)
$39.28
(+67%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (8x PE), but valuation improves significantly next year (7x PE) as earnings recover.
Forward PE: 7.89 | Forward EPS (Implied): $2.98
Bull Case
$28.41
(+21%)
Analyst growth 15.0%, PE expands to 8.3
Base Case
$23.53
(0%)
Market implied 0.0%, PE stable at 7.9
Bear Case
$18.00
(-24%)
Severe decline -15.0%, PE contracts to 7.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 6.5 to 6.7
Stabilization Target:
$24.14
(+2.6%)
PE Expansion Potential:
+2.6%
Share & Embed Analysis
Last updated: May 14, 2026 10:08 PM ET
Data refreshes hourly during market hours. Next update: 11:08 PM
Data refreshes hourly during market hours. Next update: 11:08 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PCRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
11
Sells
Net
INSIDERS SELLING
Recent Transactions
Shawn Cross
SELL
12941 shares
2026-04-23
Shawn Cross
SELL
1500 shares
2026-04-22
Shawn Cross
SELL
2845 shares
2026-04-21
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$136 | 60 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$102 | 59 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 56 HOLD |
